IMW 2019 | Immunotherapeutic approaches to myeloma
David Avigan
• 13 Sep 2019
David Avigan, MD, Harvard Medical School, Boston, MA, gives an update on the immunotherapeutic approaches to multiple myeloma (MM) at the International Myeloma Workshop (IMW) 2019, held in Boston, MA. The most recent efficacy data on the use of CAR T-cells targetting BCMA for MM is discussed as is the use of bispecific antibodies, bispecific T-cell engagers (BiTEs), antibody-drug conjugates and vaccine therapies.
